Clinical treatment

The invention relates to the use of an effective dose of N-acetyl-L-cysteine, or a dimeric form thereof, for the manufacturing of a drug for reverting mammalian neoplasia cells of epithelial origin back to a normal differentiation whereby the abnormal proliferation of the neoplasia cells is reverted to a normal pathway.

Use

The present invention relates to the use of substances with oxytocin for the preparation of pharmaceutical composition against inflamation. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against inflamation.

Use of substances having oxytocin activity for preparation of medicaments for the treatment of affective pain syndromes

Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

The present invention relates to the use of substances with oxytocin activity for the preparation of a pharmaceutical composition against cancer in situ and cervicitis. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis. It also relates to a compound of the formula SEQ ID NO:2.

Substances in order to achieve preference and create acceptance

The present invention relates to the use of substances with oxytocin activity in order to achieve preference and create acceptance. It also relates to a composition comprising at least one substance with oxytocin activity in order to achieve preference and/or create acceptance. It also relates to a composition containing at least one substance with oxytocin activity and at least one flavouring or fragrance agent in order to create acceptance.

Use of substances having oxytocin activity for preparation of medicaments for wound healing

Deposition of silver layer on nonconducting substrate

Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group or gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform-films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

Use of substances having oxytocin activity for preparation of medicaments for wound healing

Substances having oxytocin activity can be used for the preparation of a pharmaceutical composition for the curative or prophylactic treatment of wounds, such as chronic wounds. The wound healing effect can be strengthened or prolonged by combining oxytocin with estrogen.

Use of substances with oxytocin activity against climacteric disorders

The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against climacteric disorders.

N-acetyl-L-cysteine for use in in vitro fertilization

The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.

Use of substances with oxytocin activity against climacteric disorders

The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against climacteric disorders.

Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

A method of treating cancer in situ and cervicitis is disclosed. A pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis and compound of the formula SEQ ID NO:2 is also disclosed.

Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis

The present invention relates to the use di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for the preparation of a pharmaceutical composition in order to create eustasis. The invention also relates to di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for medical use, as well as a pharmaceutical composition comprising at least one di-, tri- or tetrapeptide fragment of oxytocin or mesotocin in order to create eustasis.

Use of substances with oxytocin activity against climacteric disorders

The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmacetucial composition comprising at least one substance with oxytocin activity against climacteric disorders.

Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis

The present invention relates to the use di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for the preparation of a pharmaceutical composition in order to create eustasis. The invention also relates to di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for medical use, as well as a pharmaceutical composition comprising at least one di-, tri- or tetrapeptide fragment of oxytocin or mesotocin in order to create eustasis.

UV LIGHT EMITTING DIODE AS LIGHT SOURCE IN GAS CHROMATOGRAPHY-UV ABSORPTION SPECTROPHOTOMETRY

An apparatus for analyzing a sample, including a sample receiving device, a gas chromatograph and a spectrophotometer, said spectrophotometer including a UV Light Emitting Diode as the light source, an elongated chamber and a detector. The UV light source is arranged to illuminate sample substances conducted through the chamber, and the detector is arranged to identify sample substances by UV absorption spectroscopy. 1. An apparatus for analyzing a sample , comprising a sample receiving device , a gas chromatograph and a least one spectrophotometer , said spectrophotometer comprising a LED UV light source , at least one elongated chamber and at least one detector , wherein at least one LED UV light source is arranged for illumination of sample substances conducted through the chamber , and wherein the detector is arranged for identification of sample substances by UV absorption spectroscopy , wherein the apparatus comprises LED UV light source that is a Light Emitting Diode , a LED , with a spectral range emitting shorter wavelengths than visible light from 120 to 390 nm.2. An apparatus for analyzing a sample , comprising a sample receiving device , a gas chromatograph and a spectrophotometer , said spectrophotometer comprising a LED UV light source , where the LED is in close proximity to the optical fiber to allow light to enter directly in to the optical fiber without any focusing device , an elongated chamber and a detector , wherein the LED UV light source is arranged for illumination of sample substances conducted through the chamber , and wherein the detector is arranged for identification of sample substances by UV absorption spectroscopy , wherein the apparatus comprises LED UV light source that is at least one Light Emitting Diode , a LED , with a spectral range emitting shorter wavelengths than visible light from 120 to 390 nm.3. The apparatus according to claim 1 , wherein the light source utilizes sub wave lengths below 390 nm from a broad spectrum ...

N-ACETYL-L-CYSTEINE FOR USE IN IN VITRO FERTILIZATION

The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed. 114-. (canceled)15. A pharmaceutical composition comprising N-acetyl-L-cysteine (NAC) in an amount sufficient for treatment of an indication associated with in vitro fertilization (IVF) in a mammal.16. The pharmaceutical composition of claim 15 , wherein the indication comprises implantation failure in IVF.17. The pharmaceutical composition of claim 15 , wherein the NAC is present in an amount of 600-1800 mg.18. The pharmaceutical composition of claim 15 , wherein the composition is formulated for intravenous or oral administration.19. The pharmaceutical composition of claim 15 , further comprising one or more of (i) seleniumin the form of selenomethionine and (ii) melatonin or a pharmaceutically acceptable salt thereof.20. A method for treating an indication associated with in vitro fertilization (IVF) in a mammal comprising:administering N-acetyl-L-cysteine (NAC) to the mammal.21. The method of claim 20 , wherein the indication comprises implantation failure in IVF.22. The method of claim 20 , wherein the NAC is administered intravenously at a dose of 50-150 mg/kg body weight for 1-3 days.23. The method of claim 22 , wherein the NAC is administered once a day.24. The method of claim 23 , wherein the NAC is administered at a dose of 50 mg/kg body weight on the same day as IVF treatment.25. The method of claim 24 , wherein the NAC is administered one hour before the IVF treatment.26. The method of claim 22 , wherein the NAC is administered at a dose of 50 mg/kg body weight for one day.27. The method of claim 26 , wherein the NAC is administered the morning of the day of IVF treatment.28. The method of claim 20 , wherein the NAC is administered orally at a dose of 30-45 mg/kg body weight for 1-3 days.29. The method of claim 28 , wherein the NAC is administered once a day.30. The method of claim 20 , wherein the NAC ...

N-acetyl-L-cysteine for use in in vitro fertilization

Composición farmacéutica que comprende N-acetil-L-cisteína (NAC) como tal o junto con (ii) selenio en forma de selenometionina y/o (iii) melatonina y/o sales fisiológicamente aceptables de la misma para uso terapéutico en el tratamiento de FIV de un mamífero, caracterizada porque se administra una dosis de 50-150 mg/kg de peso corporal de NAC una vez al día durante 1-3 días por vía intravenosa o en una dosis de 30-45 mg/kg de peso corporal de NAC una vez al día por vía oral o, alternativamente, 600 mg de NAC se administra tres veces al día oralmente en tres días consecutivos a la semana seguidos de cuatro días sin medicación para una duración total de tres meses o más antes del tratamiento de FIV. Pharmaceutical composition comprising N-acetyl-L-cysteine (NAC) as such or together with (ii) selenium in the form of selenomethionine and / or (iii) melatonin and / or physiologically acceptable salts thereof for therapeutic use in the treatment of IVF of a mammal, characterized in that a dose of 50-150 mg / kg body weight of NAC is administered once daily for 1-3 days intravenously or in a dose of 30-45 mg / kg body weight of NAC once a day orally or, alternatively, 600 mg of NAC is administered three times a day orally on three consecutive days a week followed by four days without medication for a total duration of three months or more before IVF treatment .

Object that resists microbiological growth consisting of a non-conductive substrate coated with a funnel coated with a method of depositing

Laser apparatus for heat treatment

An apparatus for therapeutic treatment of a living being, comprising an energy source operable to generate heat in a surface structure of tissue, for example a laser light source (102) configured to radiate laser light on a surface; a control unit (104) coupled to the energy source and configured to control the exposure of heat generating energy to the surface; wherein the control unit is configurated to control the characteristic of the radiation of the first laser light source and second laser light source such that the relation between the output energy from the first laser light source and the output energy from the second laser light source is within a predetermined range. (Fig 1)

Stimulation and registration sequence adaptable sensation measuring apparatus

An adaptable sensation measuring apparatus having an interface mechanism for interfacing with a selectable stimulation sequence control mechanism comprising different stimulation sequences.

Use of substances with oxytocin activity for the preparation of a pharmaceutical composition against inflammation

The present invention relates to the use of substances with oxytocin for the preparation of pharmaceutical composition against inflamation. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against inflamation.

Laser apparatus for heat treatment

An apparatus for therapeutic treatment of a living being, comprising an energy source operable to generate heat in a surface structure of tissue, for example a laser light source (102) configured to radiate laser light on a surface; a control unit (104) coupled to the energy source and configured to control the exposure of heat generating energy to the surface; a temperature sensor (106) configured to detect the temperature of the exposed surface and coupled to the control unit; wherein the control unit is configured to control the characteristic of the energy exposure dependent on the detected temperature of the radiated surface.

Use of substances with oxytocin activity against climacteric disorders

The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmacetucial composition comprising at least one substance with oxytocin activity against climacteric disorders.

New use I

Substances having oxytocin activity can be used for the preparation of a pharmaceutical composition for treatment or prophylaxis of affective pain syndromes, such as fibromyalgia and navel colic. The pain relieving effect can be strengthened or prolonged by combining oxytocin with oestrogen.

CHEMICAL DEPOSITION OF A SILVER LAYER ON A NON-CONDUCTIVE SUBSTRATE.

Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group or gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

Apparatus for providing an individually scaled level indication of a sensation

An sensation level measuring or analysing apparatus and method comprising the steps of receiving as an input a first threshold value in the shape of a first absolute level of a physical stimulus; receiving as an input a second threshold value in the shape of a second absolute level of the physical stimulus; dividing the range between said first and second registered absolute levels of the physical stimulus into a predetermined number of steps each having a step value; registering a third absolute level of the physical stimulus that is perceived to be comparable to an experienced sensation; and assigning said third registered absolute level of the physical stimulus the value of a corresponding scale step representing a sensation measurement value.

Deposition of silver layer on nonconducting substrate

Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group or gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

Uv light emitting diode as light source in gas chromatography-uv absorption spectrophotometry

An apparatus for analyzing a sample, comprising a sample receiving device (14), a gas chromatograph (13) and a spectrophotometer (1), said spectrophotometer (1) comprising a UV Light Emitting Diode as the light source (6), an elongated chamber (3) and a detector (15), wherein the UV light source (6) is arranged to illuminate sample substances conducted through the chamber (3), and wherein the detector (15) is arranged to identify sample substances by UV absorption spectroscopy.

Combination comprising n-acetyl-l-cysteine, selenomethionine and melatonine for treatment of anxiety disorder

A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.

Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung

Lasergerät für die wärmebehandlung

Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis

Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome

Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

Verwendung von substanzen mit oxytocin aktivität mit dem ziel der zellregeneration

Method and device for therapy

Wirkstoffe zur erzeugung von vorzug und annahme

System and method for breath sampling and breath analysis

A system and a method for breath analysis. The system comprising a breath sampling apparatus configured for collecting a sample of substances from the exhalation breath of a test subject; and a sample preparation apparatus configured for extracting selected analytes from a collected sample of substances. The method of breath analysis comprising: placing a sampling disc in the proximity of xhalation openings of a test person; receiving exhalation breath on the sampling disc for a predetermined period of for example about 1 hour; collecting a sample of substances from the exhalation breath by adsorption on the sampling disc, wherein the adsorbed amount and composition of substances corresponds to the average amount and composition of substances exhaled during a length of time; placing the sampling disc with the collected substances in a desorption vessel; releasing the collected substances from the sampling disc in the desorption vessel by heating in an inert atmosphere; preparing the sample by adsorption of selected analytes among the sample of substances; analyzing said selected analytes by means of gas chromatography.

Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis

System and method for breath sampling and breath analysis

A system and a method for breath analysis. The system includes a breath sampling apparatus for collecting substances from the exhalation breath of a test subject; and a sample preparation apparatus for extracting selected analytes. The method includes: placing a sampling disc in the proximity of exhalation openings of a test person; receiving exhalation breath on the sampling disc for a predetermined period of for example about 1 hour; and collecting a sample of substances from the exhalation breath by adsorption on the sampling disc. The adsorbed amount and composition of substances corresponds to the average amount and composition of substances exhaled during a length of time; placing the sampling disc with the collected substances in a desorption vessel; releasing the collected substances from the sampling disc in the desorption vessel by heating in an inert atmosphere; preparing the sample by adsorption of selected analytes among the sample of substances; and analyzing selected analytes by gas chromatography.

Verwendung von substanzen mit oxytocin aktivität gegen klimakterische beschwerden

Substances in order to achieve preference and create acceptance

The present invention relates to the use of substances with oxytocin activity in order to achieve preference and create acceptance. It also relates to a composition comprising at least one substance with oxytocin activity in order to achieve preference and/or create acceptance. It also relates to a composition containing at least one substance with oxytocin activity and at least one flavouring or fragrance agent in order to create acceptance.

Wirkstoffe zur erzeugung von vorzug und annahme

Wirkstoffe zur erzeugung von vorzug und annahme

Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis

The present invention relates to the use di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for the preparation of a pharmaceutical composition in order to create eustasis. The invention also relates to di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for medical use, as well as a pharmaceutical composition comprising at least one di-, tri- or tetrapeptide fragment of oxytocin or mesotocin in order to create eustasis.

Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

A method of treating cancer in situ and cervicitis is disclosed. A pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis and compound of the formula SEQ ID NO:2 is also disclosed.

Apparatus for providing an indication of a sensation

An apparatus for measuring the level of a sensation, perception or integrated skill of a person, the apparatus being provided with stimulating means for inducing a physical stimulus to the person and means for registering a sensation level value in response to an indication signal from the person that the induced stimulus corresponds to the sensation to be measured. The apparatus is devised to provide a pulsating stimulus having means for varying the increase rate of the physical stimulus in order to ensure reliability in the measurement. In a further development of the invention, the apparatus is devised to selectively deliver a first physical stimulus that is comparable with an affective component of a sensation or a second physical stimulus that is comparable with a sensory component of a sensation.

New clinical treatment

New clinical treatment

The invention relates to the use of an effective dose of N-acetyl-L-cysteine, or a dimeric form thereof, for the manufacturing of a drug for reverting mammalian neoplasia cells of epithelial origin back to a normal differentiation whereby the abnormal proliferation of the neoplasia cells is reverted to a normal pathway.

Use of substances with oxytocin activity in order to create well-being

Use of substances with oxytocin activity in order to create well-being

The present invention relates to the use of substances with oxytocin activity in order to create well-being. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity in order to create well-being.

Apparatus for providing an indication of selected components of a sensation

Apparatus for providing an indication of selected components of a sensation

An apparatus for measuring the level of a sensation, perception or integrated skill of a person, the apparatus being provided with stimulating means for inducing a physical stimulus to the person and means for registering a sensation level value in response to an indication signal from the person that the induced stimulus corresponds to the sensation to be measured. The apparatus is devised to provide a pulsating stimulus having means for varying the pulsating properties of the stimulus with pulse width modulation in order to measure the affective component of sensations. Further developments of the apparatus is also provided with amplitude variation means in order to measure the sensory component of sensations.

Use of ngf for the manufacturing of a drug for treating allergic disorders

Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis

The present invention relates to the use di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for the preparation of a pharmaceutical composition in order to create eustasis. The invention also relates to di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for medical use, as well as a pharmaceutical composition comprising at least one di-, tri- or tetrapeptide fragment of oxytocin or mesotocin in order to create eustasis.

Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

the present invention relates to the use of substances with oxytocin activity for the preparation of a pharmaceutical composition against cancer in situ and cervicitis. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis. It also relates to a compound of the formula SEQ ID NO:2.

Substances in order to achieve preference and create acceptance

The present invention relates to the use of substances with oxytocin activity in order to achieve preference and create acceptance. It also relates to a composition comprising at least one substance with oxytocin activity in order to achieve preference and/or create acceptance. It also relates to a composition containing at least one substance with oxytocin activity and at least one flavouring or fragrance agent in order to create acceptance.

Apparatus for providing an individually scaled level indication of a sensation

Apparatus for providing differential measurements of a sensation

System for breath analysis comprising a breath sampling apparatus and a sample preparation apparatus

A system and a method for breath analysis. The system comprising a breath sampling apparatus configured for collecting a sample of substances from the exhalation breath of a test subject; and a sample preparation apparatus configured for extracting selected analytes from a collected sample of substances. The method of breath analysis comprising: placing a sampling disc (106) in the proximity of exhalation openings of a test person; receiving exhalation breath on the sampling disc (106) for a predetermined period of for example about 1 hour; collecting a sample of substances from the exhalation breath by adsorption on the sampling disc (106), wherein the adsorbed amount and composition of substances corresponds to the average amount and composition of substances exhaled during a length of time; placing the sampling disc (106) with the collected substances in a desorption vessel (200); releasing the collected substances from the sampling disc (106) in the desorption vessel (200) by heating in an inert atmosphere; preparing the sample by adsorption of selected analytes among the sample of substances; analyzing said selected analytes by means of gas chromatography.